Dr. Reddy's Laboratories Limited (DRREDDY) — Financial Results | 9 May 2025(3 announcements)

Dr. Reddy's Laboratories reported a 16% YoY revenue increase to ₹53.7 billion for FY25, driven by strong emerging market growth and acquisitions, though gross margin declined to 55.6% due to price erosion. The Board recommended an Rs.8 per share final dividend, approved a 5:1 stock split, and highlighted robust cash reserves of ₹124.5 billion with RoCE at 27.7%.

Dr. Reddy's Laboratories reported record FY25 revenue of ₹32,554 crores, up 17% YoY, with Q4 revenue at ₹8,506 crores, up 20% YoY. EBITDA reached ₹2,475 crores, up 32% YoY, and PAT grew 22% YoY to ₹1,594 crores. The company highlighted double-digit growth across all segments, a strong balance sheet with ₹2,454 crores net cash surplus, and strategic progress in biosimilars and global partnerships. Forward-looking statements indicate continued investment in R&D and international expansion.

Dr. Reddy's Laboratories reported a 16% YoY revenue increase to ₹325,535 million for FY25, driven by new product launches and acquisitions, with double-digit growth across segments and a 32% YoY EBITDA rise to ₹87.22 crores. The company recommended a final dividend of Rs. 8 per share and highlighted strategic investments in nutraceuticals and consumer healthcare. Gross margin stood at 58.5% for the year, while SG&A expenses rose 22% YoY due to increased marketing and personnel costs.